These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8579916)

  • 1. The ferret as a small animal model with BMU-based remodeling for skeletal research.
    Mackey MS; Stevens ML; Ebert DC; Tressler DL; Combs KS; Lowry CK; Smith PN; McOsker JE
    Bone; 1995 Oct; 17(4 Suppl):191S-196S. PubMed ID: 8579916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats.
    Meng XW; Liang XG; Birchman R; Wu DD; Dempster DW; Lindsay R; Shen V
    J Bone Miner Res; 1996 Apr; 11(4):421-9. PubMed ID: 8992872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accretion of bone mass and strength with parathyroid hormone prior to the onset of estrogen deficiency can provide temporary beneficial effects in skeletally mature rats.
    Shen V; Birchman R; Liang XG; Wu DD; Dempster DW; Lindsay R
    J Bone Miner Res; 1998 May; 13(5):883-90. PubMed ID: 9610753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats.
    Qi H; Li M; Wronski TJ
    J Bone Miner Res; 1995 Jun; 10(6):948-55. PubMed ID: 7572319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of transient changes in trabecular bone remodeling activation.
    Weinhold PS; Gilbert JA; Woodard JC
    Bone; 1994; 15(5):577-84. PubMed ID: 7980969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between serum intact parathyroid hormone concentrations and bone remodeling in type I osteoporosis: evidence that skeletal sensitivity is increased.
    Kotowicz MA; Klee GG; Kao PC; O'Fallon WM; Hodgson SF; Cedel SL; Eriksen EF; Gonchoroff DG; Judd HL; Riggs BL
    Osteoporos Int; 1990 Oct; 1(1):14-22. PubMed ID: 2133635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
    Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
    Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats.
    Baumann BD; Wronski TJ
    Bone; 1995 Feb; 16(2):247-53. PubMed ID: 7756054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
    Shen V; Birchman R; Wu DD; Lindsay R
    J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.
    Cheng Z; Yao W; Zimmermann EA; Busse C; Ritchie RO; Lane NE
    J Bone Miner Res; 2009 Feb; 24(2):209-20. PubMed ID: 18847326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats.
    Li M; Mosekilde L; Søgaard CH; Thomsen JS; Wronski TJ
    Bone; 1995 Jun; 16(6):629-35. PubMed ID: 7669439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats.
    Wronski TJ; Yen CF; Qi H; Dann LM
    Endocrinology; 1993 Feb; 132(2):823-31. PubMed ID: 8425497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.
    Fogelman I; Fordham JN; Fraser WD; Spector TD; Christiansen C; Morris SA; Fox J
    Calcif Tissue Int; 2008 Aug; 83(2):85-92. PubMed ID: 18626566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parathyroid hormone stimulates cancellous bone formation at skeletal sites regardless of marrow composition in ovariectomized rats.
    Li M; Liang H; Shen Y; Wronski TJ
    Bone; 1999 Feb; 24(2):95-100. PubMed ID: 9951776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
    Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J
    Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats.
    Fisher JE; Scott K; Wei N; Zhao JZ; Cusick T; Tijerina M; Karanam B; Duong L; Glantschnig H
    Bone; 2012 Jun; 50(6):1332-42. PubMed ID: 22445539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LY353381 x HCl: an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34).
    Sato M; Zeng GQ; Rowley E; Turner CH
    Endocrinology; 1998 Nov; 139(11):4642-51. PubMed ID: 9794476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
    Mitlak BH; Burdette-Miller P; Schoenfeld D; Neer RM
    J Bone Miner Res; 1996 Apr; 11(4):430-9. PubMed ID: 8992873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
    Ma Y; Jee WS; Chen Y; Gasser J; Ke HZ; Li XJ; Kimmel DB
    J Bone Miner Res; 1995 Nov; 10(11):1726-34. PubMed ID: 8592950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats.
    Rhee Y; Won YY; Baek MH; Lim SK
    J Bone Miner Res; 2004 Jun; 19(6):931-7. PubMed ID: 15125792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.